Trends in live birth prevalence of Down syndrome in the Northern Netherlands 1987-96: the impact of screening and prenatal diagnosis

MJM Wortelboer; BTHM de Wolf; CC Verschuuren-Bemelmans; J Reefhuis; A Mantingh; [No Value] Beekhuis; MC Cornel

Trends in live birth prevalence of Down syndrome in the Northern Netherlands 1987-96: the impact of screening and prenatal diagnosis

MJM Wortelboer^*, BTHM de Wolf, CC Verschuuren-Bemelmans, J Reefhuis, A Mantingh, [No Value] Beekhuis, MC Cornel

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)

Abstract

In the Northern Netherlands, we examined the live birth prevalence of Down syndrome (DS) and the impact of maternal serum screening (MSS) and prenatal cytogenetic diagnosis (PCD) during the period 1987-96. In this period the live birth prevalence, based on the maternal age distribution and the age specific risk of delivering a child with DS was expected to increase from 1.26 in 1987 to 1.62 in 1996. The introduction of MSS in 1991 made PCD available to women of all ages. Nevertheless, the utilization of PCD remained very stable. In 1991, 4.7% of pregnant women underwent a diagnostic test. In 1996 this percentage was 6.4%. As a result of MSS and PCD, the live birth prevalence of DS was 19% lower than expected (p

Original language	English
Pages (from-to)	709-713
Number of pages	5
Journal	Prenatal Diagnosis
Volume	20
Issue number	9
Publication status	Published - Sept-2000

Keywords

prenatal diagnosis
maternal serum screening
Down syndrome
live birth prevalence
cost-benefit
NUCHAL TRANSLUCENCY
FIRST TRIMESTER
PREGNANCY
LIVEBIRTH
AGE

Handle.net

Persistent link

Cite this

@article{32d0022c62e34392bccd8fe80549dcca,

title = "Trends in live birth prevalence of Down syndrome in the Northern Netherlands 1987-96: the impact of screening and prenatal diagnosis",

abstract = "In the Northern Netherlands, we examined the live birth prevalence of Down syndrome (DS) and the impact of maternal serum screening (MSS) and prenatal cytogenetic diagnosis (PCD) during the period 1987-96. In this period the live birth prevalence, based on the maternal age distribution and the age specific risk of delivering a child with DS was expected to increase from 1.26 in 1987 to 1.62 in 1996. The introduction of MSS in 1991 made PCD available to women of all ages. Nevertheless, the utilization of PCD remained very stable. In 1991, 4.7% of pregnant women underwent a diagnostic test. In 1996 this percentage was 6.4%. As a result of MSS and PCD, the live birth prevalence of DS was 19% lower than expected (p",

keywords = "prenatal diagnosis, maternal serum screening, Down syndrome, live birth prevalence, cost-benefit, NUCHAL TRANSLUCENCY, FIRST TRIMESTER, PREGNANCY, LIVEBIRTH, AGE",

author = "MJM Wortelboer and {de Wolf}, BTHM and CC Verschuuren-Bemelmans and J Reefhuis and A Mantingh and Beekhuis, {[No Value]} and MC Cornel",

year = "2000",

month = sep,

language = "English",

volume = "20",

pages = "709--713",

journal = "Prenatal Diagnosis",

issn = "0197-3851",

publisher = "Wiley-Blackwell",

number = "9",

}

TY - JOUR

T1 - Trends in live birth prevalence of Down syndrome in the Northern Netherlands 1987-96

T2 - the impact of screening and prenatal diagnosis

AU - Wortelboer, MJM

AU - de Wolf, BTHM

AU - Verschuuren-Bemelmans, CC

AU - Reefhuis, J

AU - Mantingh, A

AU - Beekhuis, [No Value]

AU - Cornel, MC

PY - 2000/9

Y1 - 2000/9

N2 - In the Northern Netherlands, we examined the live birth prevalence of Down syndrome (DS) and the impact of maternal serum screening (MSS) and prenatal cytogenetic diagnosis (PCD) during the period 1987-96. In this period the live birth prevalence, based on the maternal age distribution and the age specific risk of delivering a child with DS was expected to increase from 1.26 in 1987 to 1.62 in 1996. The introduction of MSS in 1991 made PCD available to women of all ages. Nevertheless, the utilization of PCD remained very stable. In 1991, 4.7% of pregnant women underwent a diagnostic test. In 1996 this percentage was 6.4%. As a result of MSS and PCD, the live birth prevalence of DS was 19% lower than expected (p

AB - In the Northern Netherlands, we examined the live birth prevalence of Down syndrome (DS) and the impact of maternal serum screening (MSS) and prenatal cytogenetic diagnosis (PCD) during the period 1987-96. In this period the live birth prevalence, based on the maternal age distribution and the age specific risk of delivering a child with DS was expected to increase from 1.26 in 1987 to 1.62 in 1996. The introduction of MSS in 1991 made PCD available to women of all ages. Nevertheless, the utilization of PCD remained very stable. In 1991, 4.7% of pregnant women underwent a diagnostic test. In 1996 this percentage was 6.4%. As a result of MSS and PCD, the live birth prevalence of DS was 19% lower than expected (p

KW - prenatal diagnosis

KW - maternal serum screening

KW - Down syndrome

KW - live birth prevalence

KW - cost-benefit

KW - NUCHAL TRANSLUCENCY

KW - FIRST TRIMESTER

KW - PREGNANCY

KW - LIVEBIRTH

KW - AGE

M3 - Article

SN - 0197-3851

VL - 20

SP - 709

EP - 713

JO - Prenatal Diagnosis

JF - Prenatal Diagnosis

IS - 9

ER -

Trends in live birth prevalence of Down syndrome in the Northern Netherlands 1987-96: the impact of screening and prenatal diagnosis

Abstract

Keywords

Handle.net

Fingerprint

Cite this